Scale CGT Manufacturing—Without Compromise
Cell and gene therapy (CGT) manufacturing is entering a new era. As the industry transitions from clinical development to commercial-scale production, CGT manufacturers face mounting pressure to maintain compliance, ensure patient safety, and accelerate timelines—all while managing the complexities of batch-of-one production. Digital transformation is no longer a future consideration; it's the foundation of sustainable scale. This industry brief, drawn from a panel discussion with CGT manufacturing experts, explores how connected digital systems are reshaping the way quality, manufacturing, and asset management work together—and what your organization needs to build a scalable, audit-ready operation.
You’ll learn:
In CGT manufacturing, siloed systems create dangerous gaps. When quality records, manufacturing execution, and equipment data operate independently, critical information is delayed, traceability suffers, and compliance becomes reactive rather than proactive. The most successful CGT manufacturers are those who have built connected digital environments, where every batch step, deviation, and process parameter is automatically linked to quality records in real time. This level of connectivity isn't just an operational advantage. It's the infrastructure that enables manufacturers to scale confidently, respond quickly to issues, and demonstrate compliance to regulators when it matters most.
Read the brief and get strategies that matter most to CGT scale.
Download the Brief NowAligning FDA and EMA standards is achievable, and connected digital tools can turn that compliance burden into a competitive edge. Read the brief to learn how.
The paperless journey starts with one high-impact area, but knowing which technology delivers the fastest gains on quality and release times is the real advantage. Find out inside.
AI, real-time analytics, and modular facilities will reshape the industry — but which investments matter most right now? Our panelists map out the full future-ready roadmap.
Yes. A phased approach—from digital document management to connected manufacturing execution—allows CGT organizations to build digital infrastructure alongside production growth.
MasterControl's connected platform unifies quality, manufacturing, and asset management processes in a single environment, giving CGT manufacturers the visibility, traceability, and control needed to scale from clinical development to commercial production without ever compromising compliance or patient safety.
MasterControl's Manufacturing Excellence (Mx) solution connects digital batch records, deviation tracking, and process execution in a single environment, delivering the real-time visibility CGT manufacturers need to maintain consistent batch outcomes.
MasterControl Quality Excellence (Qx) embeds compliance checks directly into production workflows, ensuring every deviation, change, and process parameter is captured, linked, and audit-ready, without the manual effort of traditional paper-based systems.
MasterControl's Asset Excellence (Ax) keeps calibration records, maintenance schedules, and equipment utilization data accessible in real time, ensuring your equipment never becomes the bottleneck in a patient-critical manufacturing process.
With over 1,200 life sciences companies worldwide relying on MasterControl, the fully integrated platform is proven to help organizations reduce costs, accelerate time to market, and build the digital infrastructure needed for commercial CGT success.